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The use of cyclosporine has been restricted by its
nephrotoxic effects mediated, in part, by reactive oxygen
species (ROS). Phosphoinositide 3-kinase, protein kinase B,
and extracellular regulated kinase (ERK) pathways are related
to survival and cell death and are activated after ROS
generation. In this study, we evaluated the effects of
cyclosporine on these pathways and their contribution to
cyclosporine-induced toxicity. Viability of cells derived from
the proximal tubule of transgenic mice was measured with
Trypan Blue, ROS generation by a fluorescent probe, while
ERK and phosphoinositide 3-kinase/protein kinase B
activation were monitored with phospho-specific antibodies.
Cyclosporine decreased cell viability and induced ROS
generation and ERK and phosphoinositide 3-kinase
activation. Both pathways were activated by the epidermal
growth factor receptor (EGFR). Antioxidants blocked ERK
activation but failed to inhibit protein kinase B
phosphorylation or prevent cyclosporine toxicity.
ERK inhibition did not protect from cyclosporine-induced
cell death. EGFR or phosphoinositide 3-kinase inhibitors
protected from cyclosporine-triggered cell death
without decreasing ROS. Small interfering RNA against the
catalytic subunit of phosphoinositide 3-kinase decreased
protein kinase B phosphorylation but did not prevent
cyclosporine-mediated cell death. Our results show that EGFR
mediates the cytotoxic effects of cyclosporine through an
ROS-independent mechanism. Cyclosporine-induced cell
death is triggered by a non-classical phosphoinositide
3-kinase and does not require ERK activation.
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The immunosupressor cyclosporine A (CsA) has been widely
used to prevent organ transplant rejection. CsA has also
potential therapeutic use in the treatment of cancer and a
diversity of autoimmune diseases. The beneficial effects of
CsA are restricted by its toxic side effects, with nephrotoxicity
being the most remarkable one.1 The molecular mechanisms
responsible for these adverse effects are largely unknown. A
potential involvement of reactive oxygen species (ROS) has
been suggested,2–4 although others do not support a direct
link between CsA-mediated ROS generation and adverse
renal effects.5 CsA-induced ROS generation and susceptibility
to ROS are highly tissue-specific.6 Phosphoinositide 3-kinase/
protein kinase B (PI3K/PKB) and extracellular regulated
kinase (ERK) are among those pathways activated by
oxidative stress,7 and both of them have been implicated in
survival and death responses in the cell.
The evolutionary conserved PI3K family is implicated in a
wide range of biological processes such as cell survival,
proliferation, inflammation, adhesion, glucose metabolism,
chemotaxis, and cancer.8,9 PI3Ks are divided into three
classes according to their structure and in vitro substrate
specificities, and all of them are targeted by the pharmaco-
logical inhibitors Wortmannin, LY294002, and Apigenin.10
The ubiquitously expressed class IA PI3Ks are comprised of a
110-kDa catalytic subunit (p110a, p110b, or p110d) that is
constitutively bound to a regulatory subunit (p85a, p55a,
p50a, p85b, or p55g) and are activated by receptor tyrosine
kinases. The single class IB PI3K is primarily found in
hematopoietic cells, is composed of a catalytic subunit
(p110g) bound to a p101 regulatory subunit, and acts
downstream of G protein-coupled receptors. It has been
described that only class I PI3Ks can produce
PtdIns(3,4,5)P3, which act as docking sites for downstream
effectors such as PDK-1, PKB, SOS, and PLCg. In contrast to
class I PI3Ks, class II PI3Ks lack regulatory subunits,
phosphorylate PtdIns(4,5)P2 poorly in vitro, and appear to
associate with and function downstream of a number of
transmembrane proteins, including clathrin, integrins, che-
mokine receptors, and growth factor receptors.9–11 Class III
PI3K is composed of a catalytic homolog of the Vps34
protein, which is implicated in vesicle sorting, and a p150
regulatory subunit.11 While diverse effects have been assigned
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to class I PI3Ks, the functions of class II and class III PI3Ks
are still being elucidated.
The ERK pathway plays a critical role in gene expression,
cell growth, differentiation, and apoptosis. Activated
tyrosine kinase receptors induce translocation of Grb2/SOS
complex to the membrane that leads to GTPases
activation and the recruitment of Raf to the membrane.
Once activated, Raf phosphorylates and activates
MAPK/ERK kinase (MEK) which in turn phosphorylates
and activates ERK.12 Activation of the ERK pathway has
been repeatedly shown to contribute to cell survival
and chemoresistance.13–15 However, other studies have
evidenced a link between ERK1/2 activation and cell
death.16–18 Activation of ERK1/2 is required for the apoptotic
effects of cysplatin,17 etoposide,18 and neurodegenerative
diseases.19 When ERK activation enhances survival, the
activation occurs rapidly and is more transient, whereas in
situations where it is apoptotic, the activation tends to be
delayed and sustained.20 CsA induces ERK activation in
various cell types21,22 but the specific mechanism remains
unknown.
The PKSV-PCT cell line, derived from the convoluted
portion of the proximal tubule of kidneys from transgenic
mice, has been shown to be a useful model for the studies on
the effects of CsA in renal cells.23 Thus, the aim of this study
was to study the effects of CsA on ERK and PI3K pathways
and the potential involvement of these pathways on CsA-
induced toxicity in PKSV-PCT cells.
RESULTS
CsA induces cell death
PCT3 cells were seeded as indicated in Materials and
Methods; and after 24 h, medium was replaced by a starving
medium for an additional 16 h. This was set as standard
working conditions. Cells were then treated with CsA for
the indicated times and doses. As observed in Figure 1a,
medium replacement did not induce growth arrest in
untreated cells, where cell number still increased for the next
48 h. Treatment with doses lower than 5 mg ml1 resembled
control. Treatment with 5 mg ml1 slowed down cell pro-
liferation when compared to untreated cells, but no toxicity
was observed. Doses of 10 mg ml1 or higher induced
cytotoxicity as observed in a decrease in number of cells that
excluded the dye after 12–24 h of incubation with CsA. These
results showed that CsA toxicity was time- and dose-
dependent, and that CsA-induced cell death is a relatively
late event.
Treatment of PCT3 cells for 24 h with 25 mg ml1 of
CsA decreased cell adhesion and induced changes in
cell morphology (Figure 1b, upper panel). In order to
assess the nature of CsA-induced cell death we stained
cells with Hoescht. Nuclear staining of CsA-treated PCT3
cells did not show chromatin condensation (Figure 1b,
lower panel). Moreover, CsA treatment with 25 mg ml1 did
not increase p53 levels at any of the time points studied (data
not shown).
CsA activates ERK and PI3K pathways
ERK and PI3K pathways are two important pathways related
with cell death and survival. Thus we asked whether CsA
exerts any effect over these pathways. PI3K activation was
monitored by determining the phosphorylation status of
PKB, the best characterized target for PI3K-derived lipid
products. ERK and PKB activation were monitored by
measuring the levels of activating phosphorylations (Thr202/
Tyr204 for ERK1/2 and Ser473 for PKB) using phospho-
specific antibodies (Figure 2). CsA induced ERK and PKB
activation in a time- and dose-dependent manner. Doses
lower than 5 mg ml1 did not induce any significant
activation, but ERK and PKB phosphorylation was observed
with doses of 10 mg ml1 or above. Phosphorylation kinetics
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Figure 1 | CsA induces cell death in PCT3 cells. (a) PCT3 cells
were seeded as indicated in Materials and Methods and then treated
with increasing doses of CsA or vehicle alone for the indicated times.
Cell viability was analyzed by Trypan Blue assay. The data are the
means of three experiments performed on different days taking the
number of cells at the onset of the experiment as 100%. (b) PCT3
cells were treated with 25mg ml1 CsA or vehicle alone for 24 h and
then fixed with paraformaldehyde and stained with Hoescht as
indicated in Materials and Methods. Then cells were visualized by
phase-contrast microscopy (upper panel) and fluorescence
microscopy (lower panel).
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differed between both enzymes. PKB activation was observed
within minutes of CsA addition reaching a maximal value
after 1 h of treatment, whereas ERK activation started to be
evident after 1 h of CsA addition and reached a maximal
value after 6 h of treatment (Figure 2c).
ERK but not PKB activation in response to CsA is mediated by
ROS
In agreement with previous reports on other cell types,2–6 we
observed that in PCT3 cells, CsA induced ROS generation
(Figure 3a). ROS generation was time- and dose-dependent,
becoming evident at doses of 10 mg ml1 and 1–3 h after CsA
addition (data not shown). It has been described that ERK
and PKB can be activated by ROS.7 Since CsA induced both
ERK and PKB activation, we wondered if this activation was
mediated by ROS generation. For this purpose, we treated
cells with the superoxide dismutase mimetic Tiron or the
antioxidant enzyme PEG-catalase before CsA addition.
Covalent conjugation of catalase with polyethylene glycol
increases protein half-life and enhances the uptake of the
active form of this enzyme by cultured cells.24 Figure 3a
shows that ROS generation induced by 25 mg ml1 CsA was
significantly decreased by pretreatment with PEG-catalase
and Tiron, with a maximum effect when both antioxidants
were added together. Pretreatment with the antioxidants
blocked ERK activation, but not PKB activation (Figure 3b).
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Figure 2 | CsA treatment activates ERK and PKB. PCT3 cells were
treated with (a) the indicated doses of CsA for 6 h or (b) with
25mg ml1 CsA for the indicated times. ERK and PKB activation were
then analyzed by western blot with the corresponding phospho-
specific antibodies. To ensure equal amount of protein in each lane,
western blots against total protein were performed for ERK and PKB.
(c) The means of optical density (OD) values of the bands detected in
western blots of three different experiments are plotted, taking the
maximal value of phosphorylation of ERK and PKB as 100%.
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Figure 3 | CsA-induced ROS generation mediates ERK but not
PKB activation and is not involved in CsA cytotoxicity. (a) PCT3
cells were treated with 25 mg ml1 CsA or vehicle alone for 6 h and
ROS levels were detected as indicated in Materials and Methods.
When indicated, 10 mM Tiron or 15 000 U ml1 PEG-catalase were
added 30 min or 12 h, respectively, before CsA addition. The data are
the means of ROS levels of three different experiments and are
plotted taking the value obtained with 25 mg ml1 CsA as 100%.
(b) PCT3 cells treated as above were used to determine ERK
and PKB activation by western blot using phospho-specific
antibodies. (c) PCT3 cells pretreated with 15 000 U ml1
PEG-catalase for 12 h and/or 10 mM Tiron for 30 min were treated
with 25mg ml1 CsA or vehicle alone for 24 h. Cell viability was
analyzed by Trypan Blue assay. The data are the means of three
different experiments taking the number of untreated cells (vehicle
alone) as 100%.
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Antioxidants do not protect from CsA-induced cell death
It has been widely described that ROS could mediate the
nephrotoxic effects of CsA.25,26 We wondered if antioxidants
would prevent CsA-induced cytotoxicity. Figure 3c shows
that pretreatment with either PEG-catalase, Tiron, or both
did not attenuate CsA-induced cell death, suggesting that in
PCT3 cells the cytotoxic effects of CsA were not directly
related to its ability to generate ROS.
CsA-induced ERK and PI3K/PKB activation are mediated
through EGFR
ERK and PI3K pathways are two major signaling pathways
initiated at epidermal growth factor receptor (EGFR).27 We
wondered whether CsA-induced ERK and PKB activation was
a consequence of EGFR activation. Figure 4a shows that CsA
treatment induced EGFR phosphorylation at Tyr1068, a Grb2-
binding site that has been described to trigger MAPK
activation. Moreover, EGFR activation was required for
ERK and PKB activation since pretreatment with AG1478,
a specific EGFR inhibitor, blocked this activation (Figure 4b).
These results suggested that EGFR would mediate CsA
effects. Then, we tested if inhibition of EGFR would block
ROS production or would ameliorate cell death. Pretreat-
ment with AG1478 did not prevent ROS generation (Figure
4c) but rescued it from CsA-induced cytotoxicity (Figure 4d).
Pretreatment with AG1478 alone resulted in a slight
diminution of cell growth without affecting viability, as
expected when inhibiting a growth factor receptor.
CsA-induced ERK activation is mediated through Raf/MEK
activation
To gain insight on how CsA activates ERK we analyzed the
upstream elements of the ERK pathway. Treatment for 5 min
with 100 ng ml1 EGF was used as a positive control of ERK
pathway activation. Figure 5a shows that CsA treatment
activated MEK1/2. Raf-1 activity, monitored either by a
myelin basic protein-coupled assay or by analyzing Ser338
phosphorylation, was enhanced by CsA (Figure 5b), showing
a close coincidence between phosphorylation and kinase
activity as reported previously to occur in EGF-stimulated
NIH 3T3 cells.28 We next checked Ras activity and observed
that Ras was not activated by CsA treatment (Figure 5c).
ERK is not involved in CsA-induced cell death
To test the involvement of ERK in CsA-induced toxicity,
PCT3 cells were pretreated with the MEK inhibitors PD98059
and U0126 for 30 min before CsA addition. PD98059 and
U0126 selectively inhibited ERK activation, had no effect on
PKB activation (Figure 6a), and afforded little protection
against CsA (Figure 6b). This indicates that ERK was not
involved in CsA toxicity.
PI3K inhibitors Apigenin and LY294002 but not Wortmannin
block ERK activation in response to CsA
PI3K activation can have opposing effects on the ERK
pathway.29,30 As shown above, in PCT3 cells treated with
CsA, PKB is activated earlier than ERK. We evaluated the
potential involvement of the PI3K/PKB pathway in the
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Figure 4 | CsA-induced ERK and PKB activation are mediated by EGFR. (a) PCT3 cells were treated with 100 ng ml1 EGF for 5 min or
25mg ml1 CsA for the indicated times and EGFR activation was measured by western blot using a phospho-specific antibody against
Tyr1068. To ensure equal amount of protein in each lane, western blots against total EGFR protein was performed. (b) PCT3 cells were
pretreated with the EGFR-specific inhibitor AG1478 for 30 min before addition of 100 ng ml1 EGF for 5 min or 25mg ml1 CsA for 6 h. ERK and
PKB activation were measured by western blot using phospho-specific antibodies. (c) PCT3 cells were treated with 25mg ml1 CsA or
vehicle alone for 6 h and then ROS levels were detected as indicated in Materials and Methods. When indicated, AG1478 was added 30 min
before CsA addition. The data are the means of ROS levels of three different experiments and are plotted taking the value obtained with
25mg ml1 CsA as 100%. (d) PCT3 cells pretreated with AG1478 30 min before addition of 25 mg ml1 CsA or vehicle alone for 24 h. Cell viability
was analyzed by Trypan Blue assay. The data are the means of three experiments taking the number of untreated cells (vehicle alone) as 100%.
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activation of ERK1/2 in response to CsA (Figure 7a). EGF
was used as positive control for ERK and PKB activation. The
PI3K inhibitors Apigenin, LY294002, and Wortmannin
blocked PKB activation in EGF- or CsA-stimulated cells.
Interestingly, divergences were observed at the level of ERK.
PI3K inhibitors have little effects on EGF-stimulated ERK
activation. On the other side, Apigenin and LY294002
blocked ERK activation in CsA-treated cells, although
Wortmannin did not. These results were also observed at
the level of MEK. Differential effects of LY294002 and
Wortmannin on ERK activation have been shown pre-
viously.31 The different behavior in cell type dependence and
its molecular basis is still unclear.31 To explore if these effects
could be explained by changes in Raf-1, we analyzed Ser259
and Ser338 phosphorylations on Raf-1 immunoprecipitates
(Figure 7a). After EGF or CsA stimulation, Ser259 is
dephosphorylated as a previous stage for Raf-1 activation.
Pretreatment with PI3K inhibitors did not exert significant
effects on Ser259 dephosphorylation. Apigenin and LY294002,
but not Wortmannin, partially blocked Ser338 phosphoryla-
tion induced by CsA. Changes in the MEK/ERK phosphory-
lation state in response to either CsA or EGF correlated with
that of Ser338 in Raf-1.
PI3K inhibitors rescue from CsA-induced cell death
To explore if PI3K pathway was involved in CsA-induced
toxicity, PCT3 cells were pretreated with PI3K inhibitors for
30 min before CsA addition, and cell viability was assayed
24 h latter. CsA-induced cell death was rescued by PI3K
blockade, Apigenin being the most powerful among the PI3K
inhibitors tested (Figure 7b). None of these inhibitors
prevented CsA-induced ROS generation (data not shown).
siRNA against 110a catalytic subunit of class IA PI3K does not
prevent CsA-induced toxicity
It has been described that only class I PI3Ks can
produce PtdIns(3,4,5)P3 and thus activate PKB in vivo.
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Figure 5 | CsA activates MEK and Raf-1 but has no effect on Ras.
(a) PCT3 cells were treated with 100 ng ml1 EGF for 5 min or
25mg ml1 CsA for the indicated times. MEK activation was measured
by western blot using phospho-specific antibodies. (b) PCT3 cells were
treated as above and Raf-1 immunoprecipitates were blotted against
anti-phospho Ser338 of Raf-1 (lower panel) or used to measure Raf-1
activity by a myelin basic protein-coupled assay (upper graph). Values
are plotted taking the value obtained after treatment with 100 ng ml1
EGF for 5 min as 100%. (c) PCT3 cells were treated as above and Ras
activity was analyzed as described in Materials and Methods.
CsA
P-ERK
P-PKB
120
100
80
60
40
20
0
Ce
ll v
ia
bi
lity
 (%
 of
 co
ntr
ol)
Con CsA
none
PD98059
U0126
– – PD U0
b
Figure 6 | ERK inhibitors do not rescue from CsA-induced cell
death. (a) PCT3 cells were pretreated with 50mM PD98059 or 10mM
U0126 for 30 min and then cells were stimulated with 25 mg ml1 CsA
for 6 h. ERK and PKB activation were analyzed by western blot using
phospho-specific antibodies. (b) 50 mM PD98059 or 10 mM U0126 were
added 30 min before treatment with 25mg ml1 CsA for 24 h. Cell
viability was then analyzed using Trypan Blue assay. The data are the
means of three experiments performed on different days and are
plotted taking the number of untreated cells (vehicle alone) as 100%.
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Pharmacological inhibitors of PI3K target all PI3K isoforms
and at elevated concentrations could interfere with PI3K-
related kinases.10 To elucidate if class IA PI3Ks were
mediating CsA-induced cell death, we used a small interfer-
ing RNA (siRNA) directed against the 110a catalytic subunit
of class IA PI3Ks. Both EGF and CsA-induced PKB
phosphorylation was decreased by siRNA transfection
(Figure 8a). ERK activation in response to CsA was blocked
by siRNA but its response to EGF was unaffected. In
addition, PI3K 110a knockdown did not protect against
CsA-induced cytotoxicity (Figure 8b).
Class IA 110b PI3K, class II PI3K-C2a, and PI3K-C2b are also
expressed in PCT3 cells and in the mouse kidney
Among the different PI3Ks isoforms, class IA 110a and 110b
PI3Ks and class II PI3K-C2a and PI3K-C2b are considered to
be widely distributed in mammalian tissues.9 The presence of
class II PI3Ks has been reported in human kidney proximal
tubules,32 in human kidney cell lines HK-233 and HEK-293,34
and in rat kidney proximal tubule cells.35 By means of reverse
transcriptase (RT)-PCR techniques and using specific
primers for each isoform, we amplified products from
PCT3 cells’ total RNA that corresponded to class IA 110a
and 110b PI3Ks and class II PI3K-C2a and PI3K-C2b
isoforms (Figure 9). Identity of the amplified products was
further confirmed by sequence analysis.
DISCUSSION
Our results show that CsA affected PCT3 cells’ viability in a
dose-dependent manner. A decrease in cell proliferation was
observed at low doses (5 mg ml1), while higher doses
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Figure 7 | PI3K inhibitors rescue from CsA-induced cell death.
(a) 40mM Apigenin (Api), 40 mM LY294002 (Ly), or 100 nM Wortmannin
(Wor) were added 30 min before treatment with 100 ng ml1 EGF for
5 min or 25 mg ml1 CsA for 6 h. Cell extracts were
immunoprecipitated with anti-Raf-1 and Ser338 and Ser259 were
analyzed using phospho-specific antibodies. ERK, MEK, and PKB
activation were also analyzed by western blot using phospho-specific
antibodies. (b) PI3K inhibitors were added 30 min before treatment
with 25 mg ml1 CsA or vehicle alone for 24 h. Cell viability was then
analyzed using Trypan Blue assay. The data are the means of three
experiments performed on different days and are plotted taking the
number of untreated cells (vehicle alone) as 100%.
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Figure 8 | siRNA against 110a catalytic subunit of class IA PI3K
does not prevent CsA-induced toxicity. (a) PCT3 cells were
transfected with a non-silencing siRNA () or the 110a subunit of
class IA PI3K directed siRNA (þ ) as indicated in Materials and
Methods. Cells were then treated with 100 ng ml1 EGF for 5 min or
25mg ml1 CsA for 6 h, and ERK and PKB activation and PI3K 110a
levels were analyzed by western blot. (b) PCT3 cells transfected as
above were treated with 25 mg ml1 CsA or vehicle alone for 24 h and
cell viability was then analyzed using Trypan Blue assay. The data are
the means of three different experiments and are plotted taking the
number of untreated non-silencing siRNA transfected cells as 100%.
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(10–50 mg ml1) induced cell death. It has been reported that
such high doses are reached in kidneys of CsA-treated
patients,5 so these treatments could be a good approximation
to study CsA nephrotoxicity. Healy et al.36 described that in
the renal proximal tubular LLC-PK1 epithelial cell line, high
doses of CsA (21 mM or greater) induced necrosis. The lack of
chromatine condensation or increased p53 levels observed in
our study would argue against apoptosis. The molecular
mechanisms responsible for CsA cytotoxicity are poorly
understood. It has been proposed that non-physiological
ROS levels could be responsible for the cytotoxic side effects
of CsA,2,4,25,26 although others do not support a direct link
between CsA-mediated ROS generation and nephrotoxicity.5
To elucidate the mechanisms that mediate CsA cytotoxicity
we have analyzed the effects of CsA on ROS levels and on
ERK and PI3K pathways since both pathways have been
related to cell survival and death processes, and could be
activated after ROS generation.7 The data obtained with the
antioxidants PEG-catalase and Tiron show that ERK activa-
tion in response to CsA is mediated by ROS but PKB
activation and cell death are ROS-independent.
CsA-induced ERK activation was achieved through Raf-1
and MEK activation, but occurred without significant Ras
activation. We cannot rule out the possibility that other
GTPases, different from Ras, could be implicated in Raf
activation.37 A potential dual role in promoting either cell
survival or cell death has been proposed for ERK activation.
The cell fate would depend on the type of stimulus and the
intensity and length of the activation.16–19 Our results suggest
that the ERK pathway is not involved in CsA toxicity since
pretreatment with the MEK inhibitors PD98059 and U0126
afforded little rescue. Moreover, CsA-triggered ERK activa-
tion was ROS-dependent and antioxidants did not prevent
CsA-induced cell death.
EGFR is an upstream element common to the ERK and
PI3K signaling pathways.27 Our results indicate that EGFR
activation is required for ERK and PI3K activation in
response to EGF and CsA. In addition they show that EGFR
triggers the cytotoxic effects of CsA, since pretreatment with
the specific EGFR inhibitor AG1478 rescued from CsA-
induced cell death.
PI3K pathway has been mostly reported as an antiapop-
totic pathway and its inhibition may lead cells to apoptotic
death. However, in recent years it has become evident that
activation of the PI3K pathway may also promote cell death.
In this regard, inhibition of PI3K blocked cell death induced
by cadmium,38 arsenite,39 hypoxia,40 glucose deprivation,41
and serum withdrawal.42 Our results fit well with this context
since Wortmannin, LY294002, and Apigenin induced an
almost total rescue from CsA-induced cell death. As in the
case of the EGFR inhibitor, pro-survival effects of PI3K
inhibitors were not mediated by a decrease in ROS levels
(data not shown). The implication of distinct PI3K isoforms
in specific biological responses is a matter of increasing
interest in the recent years. Among PI3Ks, only class I PI3Ks
have been shown to activate PKB in vivo. PI3K inhibitors
target the ATP-binding site of all PI3K isoforms (except the
inhibitors refractory PI3K-C2a) and do not allow to discern
between the effects of individual PI3K isoforms.10 The use of
a more specific approach based on siRNA targeting the 110a
catalytic subunit of class IA PI3K showed that knocking
down this isoform did not prevent CsA-induced cell death,
although ERK and PKB phosphorylation were markedly
decreased. These results indicate that class IA 110a PI3K
isoform is not involved in the pro-death effects of CsA. Then,
CsA should also activate other PI3Ks, which would mediate
CsA cytotoxic effects. The presence of other inhibitor-
sensitive PI3K isoforms in PCT3 cells supports this idea.
In summary, our results suggest that in PCT3 cells, CsA
would activate, through EGFR, two different sets of PI3K
isoforms (Figure 10). The first one includes the class IA 110a
PI3K isoform, which would promote PKB phosphorylation,
would be implicated in ROS-dependent ERK activation, but
would not be involved in cell death. Another set of PI3K
isoforms sensitive to Apigenin, LY294002, and Wortmannin
would trigger the CsA-induced cell death in an ERK- and
ROS-independent way.
MATERIALS AND METHODS
Materials
CsA, EGF, PD98059, U0126, AG1478, Wortmannin, and LY294002
were from Calbiochem (San Diego, CA, USA). Anti-ERK1/2 and
anti-Ras were from Transduction Laboratories (Franklin Lakes, NJ,
USA). Anti-phospho Raf-1 (Ser259), anti-phospho Raf-1 (Ser338),
anti-phospho PKB/Akt (Ser473), anti-PKB, anti-phospho EGFR
(Tyr1068), anti-phospho ERK1/2 (Thr202/Tyr204), anti-PI3K 110a,
anti-p53, and anti-phospho MEK1/2 (Ser217/221) were from Cell
Signalling (Danvers, MA, USA). Anti-MEK and anti-Raf-1 (C12)
PI3K 110α
PI3K 110β
PI3K-C2α
PI3K-C2β
CypA
PC
T3
Co
n
Figure 9 | mRNA expression of PI3K isoforms in PCT3 cells.
Reverse transcriptase-PCR analyses using specific oligonucleotides for
the PI3K isoforms demonstrate the presence of transcripts for class IA
110a PI3K (Pik3ca, gene ID: 18706), class IA 110b (Pik3cb, gene ID:
74769), PI3K-C2a (Pik3c2a, gene ID: 18704), and PI3K-C2b (Pik3c2b,
gene ID: 240752) isoforms. When indicated, H2O was used as control.
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were from Santa Cruz (Santa cruz, CA, USA). Apigenin and all other
reagents were from Sigma (Saint Louis, MO, USA).
Cell culture and treatments
Immortalized cells from the convoluted portion of mouse kidney
proximal tubule PKSV-PCT cells (PCT3 clone) were cultured in a
medium A (DMEM/Ham’s F12 (1:1, v/v), 20 mM HEPES, 2 mM
L-glutamine, 12.5 mM D-glucose, 60 nM sodium selenite, 5 mg ml1
transferrin, 50 nM dexamethasone, 100 U ml1 penicillin, and
100mg ml1 streptomycin), supplemented with 2% fetal bovine
serum, 5 mg ml1 insulin, 10 ng ml1 EGF, and 1 nM triiodothyronine
at 371C in a 95:5 air/CO2 water-saturated atmosphere. For all
experiments, cells were seeded at 0.2 106 cells/ml and after 24 h
with complete medium cells were starved for 16 h in medium A
supplemented with 0.1% fetal bovine serum but not insulin, EGF, or
triiodothyronine. CsA was dissolved in ethanol and all the
pharmacological inhibitors were in DMSO. In all cases, controls
were carried out with cells treated with the corresponding vehicle
alone. After treatments, cells were washed twice with cold
phosphate-buffered saline (PBS) and harvested with lysis buffer as
in Llorens et al.43
Cell viability
After treatments, PCT3 cells were harvested and washed twice with
cold PBS, and the viable cells were counted with Trypan Blue Dye
(Gibco-Life Technologies, Grand Island, NY, USA) in a Neubauer
chamber. Living cells exclude the dye, whereas dead cells will take up
the blue dye. For Hoechst staining, cells seeded in six-well dishes were
washed twice with PBS and fixed for 15 min with 4% paraformalde-
hyde at room temperature. Then, cells were washed twice again with
PBS and stained with Hoescht (5mg ml1 in PBS) for 5 min.
Western blots
The protein content of cellular extracts was quantified by the
Bradford assay.44 Twenty-five microgram of total cell extract protein
was run on SDS-polyacrylamide gel electrophoresis gels, transferred
onto polyvinylidene difluoride membranes, and incubated with the
corresponding antibodies. The membranes were developed with the
enhanced chemiluminescence method (Pierce, Rockford, IL, USA).
Measurement of ROS generation
The assay is based on the incorporation of 20,70-dichlorofluorescein
diacetate into the cell. H2O2 and peroxidases are able to oxidize the
cleaved DCFH to DCF, which is highly fluorescent at 530 nm. To
measure CsA-induced ROS generation, cells were washed twice with
PBS, and fresh medium containing 20mM 20,70-dichlorofluorescein
diacetate was added to previously treated cells. After 30 min cells were
washed again, tripsinized, and resuspended with cold PBS. Fluorescence
was measure by flow cytometry on a FACScan flow cytometer.
Raf-1 activity
Raf-1 immunoprecipitation and kinase assay were performed as
described previously.45 Immunoprecipitated Raf was incubated for
30 min at 301C with 0.8 mM ATP, 10 mg ml1 GST-MEK, and
100 mg ml1 GST-ERK2. An aliquot of the supernatant was used for
ERK2 activity assays using 0.5 mg ml1 myelin basic protein and
0.1 mM [g-32P] ATP (400 c.p.m. pmol1). After 15 min incubation at
301C, 12 ml of 5 Laemmli loading buffer was added to the tubes
and the mixture analyzed by SDS-polyacrylamide gel electrophor-
esis. Radiolabeled bands were quantified in a PhosphoImager.
Measurement of Ras activation
The ability of Ras-GTP to bind to RBD (Ras-binding domain of Raf-
1) was used to analyze the amount of active Ras. Cell lysates (400 mg)
were incubated with 75 mg of GST-RBD bound to glutathione-
Sepharose beads for 2 h at 41C. Beads were washed four times and
bound proteins eluted by the addition of 25ml of Laemmli loading
buffer and immunoblotted with pan-Ras antibody as described
above. Fifty microgram of cell lysates was also analyzed by western
blot to ensure equal quantities of Ras in the assays.
Transfection techniques
For silencing the 110a catalytic subunit of PI3K, we used ON-
TARGETplus SMARTpool siRNA from Dharmacon (Lafayette, CO,
USA), which contained four pooled siRNA duplexes with ‘UU’
overhangs and a 50-phosphate on the antisense strand. Thus, a
mixture of several siRNAs ensured an effective depletion of PI3K
gene in the cells. A nonrelated control siRNA pool (Dharmacon)
that lacks identity with known gene targets was used as a control for
nonsequence-specific effects.
Transfections were performed using Lipofectamine Plus Reagent
(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s
recommendations. Briefly, cells were transfected with 50 nmol l1
siRNA and incubated at 371C for 4 h, at which time one volume
medium with 4% fetal bovine serum was added and the cells were
further incubated for another 3 h. Then, cells were washed with PBS
and starved for 16 h before treatments.
RNA extraction and reverse transcriptase-PCR
Total RNA was extracted from cultured PCT3 cells using total RNA
isolation system (Qiagen, Valencia, CA, USA) following the
manufacturer’s recommendations and employing the optimal
DNase treatment to remove contaminating genomic DNA. The
presence of the catalytic subunit of class IA PI3Ks 110a (Pik3ca) and
110b (Pik3cb), and the class II PI3K-C2a (Pik3c2a) and PI3K-C2b
(Pik3c2b) mRNA was analyzed by reverse transcriptase-PCR
with a SuperScript One-Step Reverse Transcriptase-PCR system
CsA
ROS EGFR
PI3K
110α
PI3K
isoforms?
Cell deathPKBERK
Figure 10 | Potential role for EGFR and PI3K on CsA-induced cell
death. CsA activates ERK and PI3K pathways. Activation of ERK by
CsA is ROS/EGFR/110a PI3K isoform-dependent. CsA-induced PKB
phosphorylation is also EGFR/110a PI3K isoform-dependent but does
not require ROS production. CsA cytotoxic effects requires EGFR but
would be mediated through other PI3K(s), different from 110a
isoform, and do not involve ROS generation or ERK activation.
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(Invitrogen) from 500 ng of total RNA using primers specific for the
individual PI3K isoforms and for cyclophilin A as a control of RNA
amount and integrity. Forward (Fw) and reverse (Rv) primer pairs
are as follows: Pik3ca Fw 50-ccaaacaacgacaagcagaa-30 and Rv
50-tatgacccagagggatttcg-30; Pik3cb Fw 50-atgtgtcaagtcgtggtgga-30
and Rv 50-agagggcacaatcgagaaaa-30; Pik3c2a Fw 50-ccacaccatttcatc
cacaa-30 and Rv 50-ttacagttgccccagaaagg-30; Pik3c2b Fw 50-tccaggat
caggtgacacag-30 and Rv 50-cacaggtttcccagaggtgt-30; and cyclophilin A
Fw 50-atggtcaaccccaccgtg-30 and Rv 50-cagatggggtagggacg-30. The
products were electrophoresed on a 1% agarose gel and visualized
with ethidium bromide.
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